Beta Bionics CCO sells 1,258 shares in open market

Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of common stock.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of common stock. On June 24, 2026, he sold 1,258 shares at a weighted average price of $15.0083 per share, under a pre-arranged Rule 10b5-1 Plan adopted on May 13, 2025. Following this sale, he directly holds 129,354 shares of common stock.

Insider Trade Summary 10b5-1

Net Seller: 1,258 shares

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 1,258 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,258	$15.0083	$19K

Holdings After Transaction: Common Stock — 129,354 shares (Direct)

Footnotes (2)

F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.
F2. The weighted average sale price for the transaction reported was $15.0083 and the range of prices were between $15.00 and $15.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 1,258 shares Weighted average sale price: $15.0083 per share Post-transaction holdings: 129,354 shares +2 more

5 metrics

Shares sold 1,258 shares Open-market sale on June 24, 2026

Weighted average sale price $15.0083 per share Common stock sale on June 24, 2026

Post-transaction holdings 129,354 shares Shares directly owned after the sale

Price range $15.00–$15.015 per share Range of prices for the reported sale

Rule 10b5-1 plan adoption date May 13, 2025 Plan governing the June 24, 2026 sale

Key Terms

Rule 10b5-1 Plan, open-market sale, weighted average sale price

3 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action: open-market sale of common stock on June 24, 2026."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $15.0083 and the range of prices were between $15.00 and $15.015."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beta Bionics (BBNX) disclose for Mark Hopman?

Beta Bionics disclosed that Chief Commercial Officer Mark Hopman sold 1,258 shares of common stock. The open-market sale occurred on June 24, 2026, at a weighted average price of $15.0083 per share, as reported in a Form 4 insider trading filing.

At what price did Mark Hopman sell Beta Bionics (BBNX) shares?

Mark Hopman sold 1,258 Beta Bionics shares at a weighted average price of $15.0083. The filing notes the sale price range was between $15.00 and $15.015 per share, with detailed trade-level pricing available upon request from the company or SEC staff.

How many Beta Bionics (BBNX) shares does Mark Hopman hold after this sale?

After the reported transaction, Mark Hopman directly holds 129,354 shares of Beta Bionics common stock. This post-transaction holding figure comes directly from the Form 4 and reflects his remaining direct ownership following the 1,258-share open-market sale.

Was the Beta Bionics (BBNX) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the 1,258-share sale was made under a Rule 10b5-1 Plan adopted on May 13, 2025. Such plans pre-schedule trades, helping insiders systematically sell shares without making day-to-day trading decisions.

Who is the insider involved in the latest Beta Bionics (BBNX) Form 4 filing?

The insider is Mark Hopman, Chief Commercial Officer of Beta Bionics. He reported an open-market sale of 1,258 shares of common stock on June 24, 2026, and now directly owns 129,354 Beta Bionics shares according to the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/25/2026 - 04:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last)

(First)

(Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE

CALIFORNIA

92618

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/24/2026		S⁽¹⁾		1,258	D	$15.0083⁽²⁾	129,354	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.

2. The weighted average sale price for the transaction reported was $15.0083 and the range of prices were between $15.00 and $15.015. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR